HTP Graphics

F2G LTD COMPLETES $30 MILLION FINANCING ROUND TO FUND PRE-CLINICAL AND CLINICAL DEVELOPMENT OF NOVEL ANTI-FUNGAL COMPOUNDS Spin-out, F2G Limited, an antifungal drug discovery and development company, announced in September the completion of a $30 million equity financing round in which two new investors (Advent Life Sciences and Novartis Bioventures) joined the existing syndicate (Sunstone Capital, Merifin Capital, K Nominees, and Astellas Venture Fund). These funds will be used to select a clinical candidate from the F3 series of advanced preclinical analogs and proceed to first in man studies. The F3 series represents a proprietary group of compounds with highly potent and selective activity against Aspergillus species and other moulds, which act via a totally novel mechanism. Aspergillus infections are a serious threat in immune-compromised patient populations and result in a high rate of mortality even with the most effective treatment currently available. Dr Richard White, chairman of F2G, commented, "We are delighted to welcome two top tier investors into F2G. We now have a first class international syndicate, including the venture arms of two major pharmaceutical companies." Dr Raj Parekh of Advent and Dr Anja König of Novartis Venture Funds will both be joining the Board of F2G. Raj Parekh, General Partner at Advent said, "The F2G molecules show a compelling and novel profile and have the genuine potential to be first and best-in-class agents for the treatment of invasive aspergillosis, which remains a serious unmet medical need. We look forward to working with Richard and the team to bring these molecules to an early clinical evaluation." www.f2g.com FOLLOW-ON LIGHTING AGREEMENT Nanoco Group plc (AIM: NANO), a world-leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announced in October that it had signed a follow-on joint development agreement with one of the world's largest lighting companies. This agreement follows the successful completion of a joint development agreement with the same lighting company, announced in August last year. The objective of this follow-on agreement is to finalise the design and manufacture of a light emitting diode (LED) light incorporating Nanoco quantum dots for retro-fitting in commercial, residential and other settings. LED lighting has many advantages over traditional lighting including long service life, reduced power consumption, compact size and shock resistance – but its colour performance is one factor that has limited its adoption. Current methods for producing white light from a blue LED tend to be weak in red wavelengths, creating the two problems that the light lacks warmth and fails to show true colours. Nanoco's quantum dots can transform blue LEDs so that they produce white light with a high colour rendering index (CRI), thereby showing true colours in domestic and office environments. In addition, as Nanoco quantum dots are tunable, any warmth of light can be produced. agreement and to be working with one of world's largest and most innovative lighting companies. Our quantum dots have the potential to unlock the many advantages of LEDs, creating a major commercial opportunity for Nanoco." www.nanocotechnologies.com Michael Edelman, Nanoco's Chief Executive Officer, said: "We're delighted to have signed this product development TB PARTNERSHIP WITH BECTON DICKINSON FOR THE SUPPLY AND DISTRIBUTION OF GENEDRIVE™ MOLECULAR POINT OF CARE PLATFORM Spin-out, Epistem (AIM: EHP), the biotechnology and personalised medicine company, has announced that it has reached agreement with Becton Dickinson (BD) for the supply and distribution of its Mycobacterium tuberculosis (TB) test on a global basis (excluding India and the Indian Sub Continent) using its Genedrive™ platform. The TB supply and distribution agreement includes an upfront payment of $1m with further milestone payments of up to $3m, alongside escalating supply volumes over the next 5 years. Genedrive™ provides a major advance in next generation molecular diagnostic testing by providing a rapid, low cost, simple to use 'Point of Care' device with high sensitivity and specificity. Genedrive™ aims to provide a 'gold standard' identification of TB and antibiotic resistance testing. The World Health Organisation (WHO) has publicly recommended that nations incorporate new rapid molecular tests for tuberculosis into their disease testing programs. The Genedrive™ platform and TB test have recently received CE-IVD registration and regulatory submissions are now in preparation for the Indian market. Globally, nearly 10 million cases of TB are reported annually and over $1bn dollars is spent annually on diagnostic testing, with India and China having the largest numbers of TB sufferers. Epistem's Genedrive™ platform has applications across a wide range of bacterial, viral and fungal and somatic mutation diseases for which the Company is developing a menu of diagnostic tests. www.epistem.co.uk 13

• Cover